Developing a vaccine for Crimean-Congo hemorrhagic fever virus
Structure-based Vaccine Design for CCHFV
This study is working on a vaccine to help protect people from Crimean-Congo hemorrhagic fever, a serious illness spread by ticks, by figuring out how to make the immune system produce strong defenses against the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10839374 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine for the Crimean-Congo hemorrhagic fever virus (CCHFV), a serious tick-borne disease that can lead to severe hemorrhagic fever. The team will analyze the virus's glycoproteins, which are crucial for the immune response, and design immunogens that can stimulate the production of protective antibodies. By understanding how these proteins interact with human antibodies, the researchers aim to develop a vaccine that targets conserved regions of the virus, potentially leading to effective prevention strategies against CCHFV outbreaks.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in or traveling to regions where CCHFV is endemic, particularly in parts of Africa, Central Asia, and the Middle East.
Not a fit: Patients who are not at risk of exposure to CCHFV or those living in regions where the virus is not present may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence and severity of Crimean-Congo hemorrhagic fever, saving lives and improving public health.
How similar studies have performed: Previous research has shown promise in developing vaccines for similar viral hemorrhagic fevers, indicating that this approach could be effective.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Mclellan, Jason Scott — University of Texas at Austin
- Study coordinator: Mclellan, Jason Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.